PTAB Again Rules in Favor of Broad in CRISPR-Cas9 Patent Dispute

Why It Matters

The judgment entrenches Broad’s licensing leverage and reshapes biotech investment risk, while prolonging legal uncertainty for firms developing CRISPR therapeutics.

Key Takeaways

• PTAB again grants Broad priority on eukaryotic CRISPR‑Cas9
• CVC failed to prove earlier conception under ordinary‑skill standard
• ToolGen and Sigma‑Aldrich interferences stay paused pending outcome
• Potential patent term extensions add years of exclusivity
• Licensing negotiations likely to favor Broad Institute

Pulse Analysis

The CRISPR‑Cas9 saga has become a textbook case of how cutting‑edge science collides with patent law. Since the first interference in 2018, the dispute has hinged on whether the Broad Institute’s early eukaryotic experiments constitute a reducible invention or whether the broader, organism‑agnostic claims of the University of California‑Vienna team should dominate. The Federal Circuit’s 2025 remand forced the PTAB to re‑evaluate its conception analysis, emphasizing the “ordinary‑skill” benchmark that determines how much experimental effort is required to achieve a working system.

In its March 2026 decision, the PTAB applied that refined standard and concluded that Broad’s October 2012 reduction to practice satisfied ordinary‑skill requirements, while CVC’s work still demanded extensive, non‑routine experimentation. By explicitly defining a person of ordinary skill as a Ph.D. researcher familiar with routine techniques, the board narrowed the evidentiary bar for future challengers. The ruling not only re‑asserts Broad’s priority but also signals that appeals must overcome a high factual threshold, as the Federal Circuit typically defers to the PTAB on such matters.

For the biotech industry, the outcome reshapes licensing dynamics and strategic planning. Companies developing CRISPR‑based therapeutics must now negotiate with Broad for access, potentially facing higher royalty rates or more restrictive field‑of‑use clauses. Meanwhile, the suspended ToolGen and Sigma‑Aldrich interferences could extend the overall patent term for successful parties, adding valuable years of market exclusivity. Stakeholders should monitor these parallel cases closely, as any shift could ripple through the entire gene‑editing ecosystem, influencing R&D pipelines, partnership structures, and investor confidence.